Garrabou Tornos, Glòria
Mostrant 121 a 140 de 152 resultats
DataTítolAutor(s)Tipus
2009Improvement of Mitochondrial Toxicity in Patients Receiving a Nucleoside Reverse-Transcriptase Inhibitor-Sparing Strategy: Results from the Multicenter Study with Nevirapine and Kaletra (MULTINEKA)Negredo, E,; Miró, Ò.; Rodríguez-Santiago, B.; Garrabou, G.; Estany, C.; Masabeu, A.; Force, L.; Barrufet, P.; Cucurull, J.; Domingo, P.; Alonso-Villaverde, C.; Bonjoch, A.; Morén, C.; Pérez-Álvarez, N.; Clotet, B.Article
2009Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemiaGarrabou, Gloria; Moren, Constanza; Gallego-Escuredo, Jose Miguel; Milinkovic, Ana; Villarroya, Francesc; Negredo, Eugenia; Giralt, Marta; Vidal, Francesc; Pedrol, Enric; Martinez, Esteban; Cardellach, Francesc; Gatell, Josep Maria; Miro, OscarArticle
2008Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimensNegredo E; Garrabou G; Puig J; Lòpez S; Morén C; Bellido R; Ayen R; Cardellach F; Miró O; Clotet BArticle
2008Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimensNegredo, Eugenia; Garrabou, Gloria; Puig, Jordi; Lopez, Sonia; Moren, Constanzo; Bellido, Rocio; Ayen, Rafaela; Cardellach, Francesc; Miro, Oscar; Clotet, Bonaventura;Article
2008Mitochondrial DNA depletion in oocytes of HIV-infected antiretroviral-treated infertile womenLopez, S.; Coll, O.; Durban, M.; Hernandez, S.; Vidal, R.; Suy, A.; Moren, C.; Casademont, J.; Cardellach, F.; Mataro, D.; Miro, O.; Garrabou, G.Article
2008Partial immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and tenofovir-based regimensNegredo E, Garrabou G, Puig J, Lòpez S, Morén C, Bellido R, Ayen R, Cardellach F, Miró O, Clotet BArticle
2007HIV-1-infected long-term non-progressors have milder mitochondrial impairment and lower mitochondrially-driven apoptosis in peripheral blood mononuclear cells than typical progressorsPeraire, J.; Miró, O.; Saumoy, M.; Domingo, P.; Pedrol, E.; Villarroya, F.; Martínez, E. et al. Article
2007The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patientsMilinkovic, A.; Martínez, E.; López, S.; de Lazzari, E.; Miró, O.; Vidal, S.; Blanco, J.L.; Garrabou, G.; Laguno, M.; Arnaiz, J.A.; León, A.; Larrousse, M.; Loncà, M.; Mallolas, J.; Gatell, J.M. Article
2007Neuroleptic treatment effect on mitochondrial electron transport chain: peripheral blood mononuclear cells analysis in psychotic patientsCasademont, J.; Garrabou, G; Miró, Ò.; López, S.; Pons A.; Bernardo M.; Cardellach, F.Article
2007Reversible inhibition of mitochondrial protein synthesis during linezolid-related hyperlactatemiaGarrabou, G.; Soriano A; López, S.; Guallar JP.; Giralt M; Vilarroya F; Martínez JA; Casademont, J.; Cardellach, F.; Mensa J; Miró, Ò. Article
2006Longitudinal study on mitochondrial effects of didanosine-tenofovir combination.López, S.; Negredo, E.; Garrabou, G.; Piug, J.; Ruiz, L.; Sanjurjo, E.; Ramos, X.; Infante, A. B.; Casademont, J.; Cardellach, F.; Clotet, B.; .Miró, Ò. Article
2006Noninvasive diagnosis of mitochondrial dysfunction in HAAART-related hyperlactatemiaGarrabou, G.; Sanjurjo E; Miró, Ò.; Martínez, E.; Infante A; López, S.; Cardellach, F.; Gatell, J.M.; Casademont, J.Article
2006A randomized open-label study comparing the impact of reducing the dose of stavudine versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HFV-infected patients: results at 48 weeksMilinkovic, A.; Martínez, E.; López, S.; de Lazzari, E.; Miró, O.; Vidal, S.; Blanco, J.L.; Garrabou, G.; Laguno, M.; Arnaiz, J.A.; León, A.; Larrousse, M.; Loncà, M.; Mallolas, J.; Gatell, J.M. Article
2006Non invasive diagnosis of mitochondrial dysfunction in HAART-related hyperlactatemia.Garrabou G, Sanjurjo E, Miro O, Martinez E, et al.Article
2006Short communication metabolic and mitochondrial effects of switching antiretroviral-experienced patients to enfuvirtide, tenofovir and saquinavir/ritonavir.Miro, O.; Garrabou, G.; Lopez, S.; Deig, E.; Vidal, I.; Infante, A. B.; Cardellach, F.; Casademont, J.; Pedrol, E.Article
2005Protease inhibitors and apoptosis: studies on peripheral blood mononuclear cells (PBMCs). Lopez S., Garrabou G., Villaroya J. et al.Article
2005Peripheral blood mononuclear cells of HIV-1-infected patients long-term non-progressors show mild mitochondrial impairment and low mitochondrially driven apoptosis.Garrabou G., Lopez S., Vidal F., et al.Article
2005Effects of different doses of didanosine combined with tenofovir on peripheral blood mononuclear cell mitochondrial parameters.Lopez S., Garrabou G., Negredo E. et al. Article
2005In vivo effects of highly active antiretroviral therapies containing the protease inhibitor nelfinavir on mitochondrially driven apoptosisMiró, O.; Villarroya, J.; Garrabou, G.; López, S.; Rodríguez de la Concepción, M.; Pedrol, E.; Martínez, E.; Giralt, M.; Gatell, J. M.; Cardellach, F.; Casademont, J.; Villarroya, F. Article
2005Tretament of symptomatic hyperlactatemia and lactic acidosis in HIV+ patients under nucleoside reverse transcriptase inhibitors.Pedrol, E.; Ribell, M.; Deig, E.; Villà, M.C.; Miró, O.; Garrabou, G.; Soler, A.Article